RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
表征 PyMT 乳腺肿瘤中浸润肿瘤的第 1 组先天淋巴细胞
英文原题：Characterizing tumor-infiltrating group 1 innate lymphoid cells in PyMT breast tumors.
查看英文原题
Characterizing tumor-infiltrating group 1 innate lymphoid cells in PyMT breast tumors.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
乳腺癌是女性中最常见的癌症，在全球范围内持续造成显著的癌症相关死亡。研究肿瘤微环境（TME）中浸润免疫亚群的复杂作用，将有助于更好地理解疾病进展，并揭示针对乳腺癌患者的新型治疗策略。多瘤病毒中T抗原的乳腺特异性表达（MMTV-PyMT）于1992年由William Muller首次建立，是乳腺癌研究中最常用的基因工程小鼠模型（GEMM）。固有淋巴细胞（ILC）由多样化的效应细胞家族组成，已知在抵御病原体、组织稳态和肿瘤免疫中发挥重要作用。在小鼠中，1型ILC由NK细胞和ILC1组成，已被证明在TME中具有不同的作用。在此，我们提供了一套详细的方法学，用于表征MMTV-PyMT乳腺肿瘤模型中的肿瘤浸润NK细胞和ILC1。
展开英文摘要原文
Breast cancer is the most common cancer in women and continues to have a significant impact in cancer-associated deaths worldwide. Investigating the complex roles of infiltrating immune subsets within the tumor microenvironment (TME) will enable a better understanding of disease progression and reveal novel therapeutic strategies for patients with breast cancer.
The mammary-specific expression of polyomavirus middle T oncoprotein (MMTV-PyMT) was first established in 1992 by William Muller and is the most commonly used genetically engineered mouse model (GEMM) for breast cancer research. Innate lymphoid cells (ILCs) are composed of a diverse family of effector cells known to play important roles in defense against pathogens, tissue homeostasis, and tumor immunity. In mice, group 1 ILCs are composed of NK cells and ILC1s, which have been shown to have differential roles within the TME.
Here, we provide a detailed methodology in characterizing tumor-infiltrating NK cells and ILC1s in MMTV-PyMT breast tumor model.
论文信息
- 作者
- Chung DC、Elford AR、Jacquelot N
- 第一作者单位
- Department of Immunology, University of Toronto, Toronto, ON, Canada; Tumor immunotherapy program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.Canada
- 通讯作者单位
- Department of Biochemistry and Molecular Biology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada; Department of Microbiology, Immunology and Infectious Diseases, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada; Arnie Charbonneau Cancer Research Institute, Calgary, AB, Canada. Electronic address: nicolas.jacquelot@ucalgary.ca.Canada
- 期刊
- Methods in cell biology2025
- 原文标识
- PubMed 39863384 · DOI 10.1016/bs.mcb.2024.03.008